Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468910 · ClinicalTrials.gov registry record · Phase 2
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT00468910 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 79 participants.
The verdict
NCT00468910, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well aspirin works in preventing colorectal cancer in patients at increased risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of aspirin may prevent colorectal cancer.
Interventions
- DRUG placebo
- OTHER laboratory biomarker analysis
- DRUG acetylsalicylic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468910
The ClinicalTrials.gov registry entry for NCT00468910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00468910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00468910 about?
NCT00468910 is a clinical study titled "Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer". This randomized phase II trial is studying how well aspirin works in preventing colorectal cancer in patients at increased risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of aspirin may prevent colorectal cancer.
What is the current status of trial NCT00468910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2007-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00468910?
The interventions under investigation include: placebo (DRUG), laboratory biomarker analysis (OTHER), acetylsalicylic acid (DRUG).
Who is sponsoring clinical trial NCT00468910?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.